BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Encap Drug Delivery Receives Patent Approval for DuoCap(TM) Capsule System


7/16/2010 2:18:36 PM

Livingston, United Kingdom, July 13, 2010 / b3c newswire / - Encap Drug Delivery, a leading provider of development and manufacturing services to the pharmaceutical industry, has received confirmation that their DuoCap™, capsule delivery system has been granted patents for US and Europe.

DuoCap™, is a single oral dosage unit that comprises a capsule-in-a-capsule and offers broad therapeutic applications. The inner and outer capsules may contain the same active drug providing multiple release profiles from the dosage unit e.g. an immediate release formulation from the outer capsule and a controlled release formulation from the inner capsule. In addition to modifying the release profiles it is also possible to target the inner and outer capsule to different areas of the GI tract (small intestine or colon) using Encap’s coating expertise. Alternatively the compartments may contain different actives for use with combination therapies or actives that are incompatible in a single capsule. Combination therapies are of currently of significant interest, demonstrated by the recent launches of Combodart™ (GSK) and Vimovo™ (Pozen / AstraZeneca).

The inner capsule may contain liquid, semi-solid, powder or pellet formulations and the outer capsule contains liquid or semi-solid formulations, an area where Encap are recognised as world leading experts. DuoCap™ offers further flexibility in that the capsule shells may be coated with either enteric systems or with Encap’s colonic delivery system, ENCODE™. The DuoCap™ delivery system is already used in two probiotic combination products which are marketed worldwide. The system is also being used by a number of major pharmaceutical companies for products in clinical development. Encap has recently signed a development and licensing agreement with a US company to develop a dual release dosage form of a drug. Terms were not disclosed.

The patented Duocap™ technology can provide protection for clients interested in novel line-extension formulations for drugs coming to the end of their patent life. Encap’s business model is to provide clients with fee-for-service and license free formulation development and manufacturing service. DuoCap™ provides clients with the additional opportunity to license a patent protected technology on a product by product basis if required.

"The issuance of these patents is an important achievement in the strengthening of Encap’s Intellectual Property portfolio," said Dr. Robbie Stewart, Sales & Marketing Director. "DuoCap was initially developed for use with probiotic treatments but now has huge potential for the delivery of many pharmaceutical active agents requiring controlled release. Another real advantage is the flexibility of our manufacturing process. Encap is able to manufacture DuoCap for clinical or proof-of-concept studies right through to full scale commercial volumes”

About Encap Drug Delivery - www.encapdrugdelivery.com Encap was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK is the world’s largest development and manufacturing facility dedicated to liquid filled hard capsules.

For further information please contact: Robbie Stewart Encap Drug Delivery, Units 4, 5 & 6 Oakbank Park Way, Livingston United Kingdom, EH53 0TH Tel: +44 (0)1506 448080. E-mail: rstewart@encapdrugdelivery.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES